.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

IMAGENT Drug Profile

« Back to Dashboard
Imagent is a drug marketed by Imcor Pharms Co and Alliance Pharm and is included in two NDAs. There is one patent protecting this drug.

This drug has thirty-two patent family members in eighteen countries.

The generic ingredient in IMAGENT is perflubron. Additional details are available on the perflubron profile page.

Summary for Tradename: IMAGENT

Patents:1
Applicants:2
NDAs:2
Formulation / Manufacturing:see details

Clinical Trials for: IMAGENT

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 2002DISCNNo5,798,091<disabled> <disabled>
Alliance Pharm
IMAGENT
perflubron
LIQUID;ORAL020091-001Aug 13, 1993DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: IMAGENT

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 20026,280,705<disabled>
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 20026,287,539<disabled>
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 20025,605,673<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: IMAGENT

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
5,798,091
IMAGENT
August 25, 2010

Non-Orange Book Patents for Tradename: IMAGENT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,706,253 Osmotically stabilized microbubble preparations<disabled in preview>
7,141,235Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement<disabled in preview>
6,280,705 Kits & systems for ultrasonic imaging<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: IMAGENT

Country Document Number Estimated Expiration
European Patent Office0711179<disabled in preview>
European Patent Office0812214<disabled in preview>
Spain2231775<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc